Loading...
•
Dec 31, 2024
Zomedica Q4 2024 Earnings Report
Zomedica reported record Q4 revenue, strong gross margins, and a reduced net loss compared to the prior year.
Key Takeaways
Zomedica's Q4 2024 revenue grew to $7.9 million, an 8% increase year-over-year, driven by 109% growth in its Diagnostics segment. The company reported a net loss of $7.2 million, a significant improvement from the $22.4 million net loss in Q4 2023. Gross margin was strong at 70.3%, while non-GAAP adjusted EBITDA loss improved to $5.4 million. Cash and cash equivalents at the end of the quarter stood at $71.4 million, supporting future growth initiatives.
Q4 2024 revenue reached a record $7.9 million, up 8% year-over-year.
Diagnostics segment revenue surged 109%, driven by TRUFORMA® adoption.
Net loss narrowed to $7.2 million, improving from $22.4 million in Q4 2023.
Strong cash position of $71.4 million provides growth runway.
Zomedica
Zomedica
Zomedica Revenue by Segment
Revenue by Segment
TRUFORMA Revenue
CapyFin.com Forward Guidance
Zomedica expects continued growth in 2025, driven by increased focus on equine markets, product launches, and strategic acquisitions.
Positive Outlook
- Expansion into equine healthcare with new product launches.
- Increased adoption of TRUFORMA® and VETGuardian® driving revenue growth.
- Optimized manufacturing capabilities to improve efficiency and margins.
- Strong cash position enables further strategic acquisitions.
- New distribution agreements expanding international reach.
Challenges Ahead
- Potential pricing pressure in the diagnostic segment.
- Competition intensifying in the veterinary diagnostics market.
- Macroeconomic uncertainty affecting capital spending by veterinary clinics.
- Higher R&D and marketing costs to support growth initiatives.
- Regulatory hurdles in expanding into new international markets.